ProCE Banner Activity


Finding the “One”: Individualizing Diabetes Management with GLP-1 Receptor Agonists

PCE On Demand Live Presentation

More than 34 million Americans are diagnosed with type 2 diabetes (T2D), and more than one half fail to achieve guideline-recommended glycemic goals, exposing them to excessive risk for T2D complications. People with T2D have a 2- to 4-fold higher risk of cardiovascular (CV) morbidity and mortality and are more likely to have factors that increase atherosclerotic CV disease risk—including hypertension, dyslipidemia, and obesity. The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) combine robust glucose-lowering efficacy with extraglycemic benefits including weight loss, significant reductions in CV events, and renal benefits for select agents, making them an attractive option for management of patients with T2D. Learn from an expert about the many benefits of GLP-1 RAs and how to apply clinical evidence and guideline-based recommendations for their use in your patients with T2D.

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: September 15, 2022

Expiration: September 14, 2023

No longer available for credit.



Deborah A. Hinnen

Deborah A. Hinnen, RN, APN, BC-ADM, CDE

Advanced Practice Nurse
Memorial Hospital
University of Colorado Health System
Denver, Colorado

Susan Tiso

Susan Tiso, DNP, FNP-BC

Consultant; Retired Clinical Professor
Sue & Bill Gross School of Nursing
Family Nurse Practitioner
Department of Family Medicine
University of California, Irvine
Irvine, California


This activity is supported by an educational grant from Novo Nordisk.

Provided by

ProCE Banner


Novo Nordisk

Target Audience

NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the mechanism of action of GLP-1 RAs as it relates the pathophysiology and progression of T2D

  • Differentiate among the GLP-1 RAs based on dosing, administration, and glycemic and extraglycemic effects

  • Apply guideline recommendations, cardiovascular and/or renal risk factors, and patient preferences to select GLP-1 RAs for appropriate patients early in the treatment of T2D

  • Incorporate strategies to manage the adverse events associated with GLP-1 RAs to promote adherence


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Debbie Hinnen, APN, BC-ADM, CDCES: consultant/advisor/speaker: Intuity, Lilly/Boehringer Ingelheim, Novo Nordisk, Sanofi.

Lucia M. Novak, MSN, ANP-BC, BC-ADM: consultant/advisor/speaker: Abbott Diabetes Care, BI/Lilly, Novo Nordisk, Prevention Bio, Xeris.

Daniel Thibodeau, DHSc, MHP, PA-C: consultant/advisor/speaker: Arbor Pharmaceuticals.

Susan Tiso, DNP, FNP-BC has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Lucia M. Novak, MSN, ANP-BC, BC-ADM and Daniel Thibodeau, DHSc, MHP, PA-C, as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: September 15, 2022
Expiration date: September 14, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Lucia M. Novak, MSN, ANP-BC, BC-ADM, Diabetes Consulting Services, North Bethesda, Maryland

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Daniel Thibodeau, DHSc, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.